Apellis Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This ESG rating covers 17 UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Decent Work & Economic Growth' and 'Life below Water'. Full ESG assessment of Apellis Pharmaceuticals Inc can be accessed by registering for free. Other companies in the scoring peer group for Apellis Pharmaceuticals Inc are shown.
Apellis Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 0.0, social score of 2.3 and governance score of 2.7.
1.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1631 | Viewbix Inc | 1.8 | Low |
| 1631 | dorsaVi Ltd | 1.8 | Low |
| 1682 | Apellis Pharmaceuticals Inc | 1.7 | Low |
| 1682 | C4 Therapeutics Inc | 1.7 | Low |
| 1682 | Abcellera Biologics Inc | 1.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Apellis Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc report the average age of the workforce?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc offer flexible work?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc conduct supply chain audits?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose water use targets?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Apellis Pharmaceuticals Inc have a product recall in the last two years?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Apellis Pharmaceuticals Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose parental leave metrics?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Apellis Pharmaceuticals Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose its waste policy?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc report according to TCFD requirements?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose energy use targets?
Sign up for free to unlockDoes Apellis Pharmaceuticals Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Apellis Pharmaceuticals Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Apellis Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.